成人异基因造血细胞移植后急性GVHD的经验证临床风险评分
验证集中,风险评分百分位越高,急性GVHD风险越大。
要点
- 该评分可识别移植后100天内急性GVHD高风险患者。
- 风险评分在验证集中显示良好的风险分层能力。
- 这是首个广泛适用的经验证急性GVHD临床风险评分。
核心结论
- 开发并验证了首个广泛适用的急性GVHD临床风险评分,能有效分层移植后100天内急性GVHD风险。
关键数值与推荐
- 主要结局为移植后100天内2-4级急性GVHD,次要结局为移植后100天内3-4级急性GVHD。
- 风险评分基于训练集开发,在验证集中测试,并分为4个百分位组。
临床怎么用
- 该评分可用于移植前或移植早期识别急性GVHD高风险患者,指导个体化预防和监测策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Acute graft-versus-host disease (aGVHD) contributes to significant morbidity after allogeneic hematopoietic cell transplantation (allo-HCT). We aimed to develop and validate a clinical score to identify patients with significantly different risk for developing aGVHD. Analysis included adults who underwent allo-HCT during 2008-2019. Eligibility criteria were widely inclusive of transplant indications, donor types, graft types, conditioning regimens, and GVHD prophylaxis regimens. The final cohort of 21 796 patients was randomly split into training and validation cohorts, with 15 258 (70%) and 6538 (30%) patients, respectively. The primary outcome was grade 2 to 4 aGVHD, and the secondary outcome was grade 3 to 4 aGVHD, by day 100 posttransplant. Risk scores were developed using the training cohort, tested using the validation cohort, and stratified into 4 percentile groups. The odds of grade 2 to 4 aGVHD by day 100 posttransplant were 1.50 (95% confidence interval [CI], 1.29-1.75; P< .0001) for the 25th to 50th percentile group, 2.0 (95% CI, 1.78-2.40; P< .0001) for the 50th to 75th percentile group, and 3.1 (95% CI, 2.72-3.65; P< .0001) for the >75th percentile group compared with the ≤25th percentile group in the validation cohort. The odds of grade 3 to 4 aGVHD by day 100 posttransplant were 1.4 (95% CI, 1.11-1.74; P = .0043) in the 25th to 50th percentile group, 2.0 (95% CI, 1.61-2.49; P< .0001) in the 50th to 75th percentile group, and 3.2 (95% CI, 2.64-3.98; P< .0001) in the >75th percentile group compared with the ≤25th percentile group in the validation cohort. Here, to our knowledge, we have developed the first validated, widely inclusive clinical risk score for the development of aGVHD after allo-HCT.
引用
- Ulschmid CM, Li X, Wang T, et al. Validated clinical risk score for acute graft-versus-host disease in adult allogeneic hematopoietic cell transplantation. Blood Adv. 2026. PMID: 41498421. doi:10.1182/bloodadvances.2025016938
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。